Artem Oganesyan, Internal Medicine Resident Physician at Jefferson Abington Hospital, shared a post on LinkedIn:
“Exciting work presented at ASH25 – the use of Imatinib in Mast Cell Activation Syndrome (MCAS) by our team from Sidney Kimmel Comprehensive Cancer Center at Jefferson.
c-KIT D816V negative MCAS treated with Imatinib showed decreased symptom severity and frequency in retrospective analysis of community practice data from Abington Hospital – Jefferson Health.
This creates unique treatment opportunities for this very challenging disease.”
Read More updates form ASH25 on OncoDaily.